Crossmark

Predictors of medication adherence among patients with severe psychiatric disorders: findings from the baseline assessment of a randomized controlled trial (Tecla)

Crossref DOI link: https://doi.org/10.1186/s12888-018-1737-4

Published Online: 2018-05-29

Published Print: 2018-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Stentzel, Ulrike https://orcid.org/0000-0002-9723-8677
van den Berg, Neeltje

Schulze, Lara N.

Schwaneberg, Thea

Radicke, Franziska

Langosch, Jens M.

Freyberger, Harald J.

Hoffmann, Wolfgang

Grabe, Hans-Jörgen
Funding

Funding for this research was provided by:

Damp Stiftung (not available)
License Information

Text and Data Mining valid from 2018-05-29
More Information

Article History

Received: 9 January 2018

Accepted: 11 May 2018

First Online: 29 May 2018

Ethics approval and consent to participate

: Tecla is approved by the Ethics Committee of the University Medicine Greifswald (BB 122/14). The committee stated that the majority of the members of the committee concluded that there are no ethical and legal concerns against the implementation of the study, and therefore approves the proposal. Tecla is retrospectively registered at 2015\05\21 at the German Clinical Trials Register (DRKS00008548). IMeS is also approved by the Ethics Committee of the University Medicine Greifswald; BB 017/15. All patients had to sign an informed consent to participate. All appropriate legal guardians or representatives were informed about the participation. All guardians or representatives indicated that the patients were capable of providing ethical consent to participate.

: The authors declare that they have no competing interests.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Document is current

Any future updates will be listed below